A double step-up dosing approach to decrease toxicity of AZD0486, a novel CD19xCD3 bsAb for NHL [Video]

Sameh Gaballa, MD, Moffitt Cancer Center, Tampa, FL, discusses an ongoing first-in-human Phase I trial (NCT04594642) investigating a novel CD19xCD3 bispecific antibody (bsAb), AZD0486, for treating patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Using a new double step-up dosing approach, the rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have been significantly decreased, improving the safety profile seen with the agent. In the follicular lymphoma (FL) cohort, responses were promising, especially given the heavily pretreated nature of this patient subgroup. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.